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Abbreviations
GH, glycoside hydrolase; CBM, carbohydrate binding modules; X6, xylohexaose; X4, xylotetraose; HGM, 
human gut microbiota; SCFA, short chain fatty acid, AX, arabinoxylan; GX, glucuronoxylan; WAX, wheat 
arabinoxylan; BGX, birch glucuronoxylan; XOS, xylo-oligosaccharide; XAXXX, 33-α-L- and 23-α-L-
arabinofuranosyl-xylotetraose; XUXXX, 23-(4-O-methyl-α-D-glucuronyl)-xylotetraose; SAD, single-
wavelength anomalous diffraction; 15N-HSQC, heteronuclear single quantum coherence spectroscopy.
Databases
Structural data are available in the PDB database under the accession number 6SGF. Sequence data are 
available in the GenBank database under the accession number EEV01588.1. The assignment of the R. 
intestinalis xylan binding module into the CBM86 new family is available in the CAZy database 
(http://www.cazy.org/CBM86.html).
Abstract 
Efficient capture of glycans, the prime metabolic resources in the human gut, confers a key competitive 
advantage for gut microbiota members equipped with extracellular glycoside hydrolases (GHs) to target 
these substrates. The association of glycans to the bacterial cell surface is typically mediated by 
carbohydrate binding modules (CBMs). Here we report the structure of RiCBM86 appended to a GH10 
xylanase from Roseburia intestinalis.  This CBM represents a new family of xylan binding CBMs present in 
xylanases from abundant and prevalent healthy human gut Clostridiales. RiCBM86 adopts a canonical β-
sandwich fold, but shows structural divergence from known CBMs. The structure of RiCBM86 has been 
determined with a bound xylohexaose, which revealed an open and shallow binding site. RiCBM86 
recognizes only a single xylosyl ring with direct hydrogen bonds. This mode of recognition is 
unprecedented amongst previously reported xylan-binding type-B CBMs that display more extensive 
hydrogen-bonding patterns to their ligands or employ Ca2+ to mediate ligand binding. The architecture of 
RiCBM86 is consistent with an atypically low binding affinity (KD≈0.5 mM for xylohexaose) compared to 
most xylan binding CBMs. Analyses using NMR spectroscopy corroborated the observations from the 
complex structure and the preference of RiCBM86 to arabinoxylan over glucuronoxylan, consistent with 
the largely negatively charged surface flanking the binding site. Mutational analysis and affinity 
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This study provides novel insight into the structural features that shape low-affinity CBMs that mediate 
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Introduction
The human gut microbiota (HGM) consists of trillions of microorganisms that exert a profound impact on 
human health, especially via modulation of host immune- and metabolic homeostasis[1,2]. The molecular 
dialogue of the microbiota with the host is typically communicated via microbial metabolites, whereby 
short chain fatty acids (SCFAs) produced from fiber fermentation play a key role[3]. The most common 
SCFAs are acetate, propionate and butyrate, all of which are considered beneficial to human health[4]. 
Notably, SCFA profiles generated from fiber fermentation are specific to distinct taxonomic groups, e.g. 
members of the dominant genus Bacteroides produce mainly acetate (and lower amounts of propionate), 
whereas members from Clostridium group XIVa group[5,6] are key butyrate producers[7]. Bacterially 
produced butyrate has received increasing attention due to its role in enforcing the gut barrier by 
increasing the proliferation rate of colonocytes and strengthening tight junctions. Moreover, butyrate 
down-regulates the expression of inflammatory cytokines and increases colonic regulatory T cells by 
inhibition of host histone deacetylases[8,9]. Thus, butyrate producers are considered an indicator of a 
healthy HGM and make a marked contribution to maintaining a balanced and healthy community in the 
human gut[10]. Despite these pronounced physiological roles, little attention has been dedicated to 
understating the interactions of butyrate producing members of the HGM with dietary glycans, as 
opposed to other taxonomic groups that are ascribed a probiotic status, e.g. bifidobacteria[11–13] and 
lactobacilli[14,15]. 
Roseburia intestinalis from the Clostridium cluster XIVa is an abundant (up to 5 % of the total microbiota) 
and prevalent butyrate producing Firmicute[7,16]. The abundance of R. intestinalis is reduced in type 2 
diabetes[17], Chron’s disease[18–20], and colorectal cancer[21] patients, which is consistent with the 
association of this species to a balanced microbiota in healthy humans. R. intestinalis has also been shown 
to adhere to mucin[22], reflecting intimate association with the host and production of butyrate close to 
the surface of the enterocytes. R. intestinalis is atypical amongst human gut Firmicutes by encoding a 
considerable repertoire (>130) of glycoside hydrolases (GHs) and polysaccharide lyases[23] indicative of 
extensive saccharolytic potential. Accordingly, R. intestinalis is an appropriate model to investigate the 
strategy of complex glycan utilisation by butyrate producing Clostridium XIVa members. 
R. intestinalis and Eubacterium rectale, both affiliated to the Clostridium XIVa, have been proposed to be 
key primary degraders of the prime dietary fiber xylan based on enrichment from faecal samples and in 
vitro growth experiments[24,25]. Xylan comprises a β-(1→4)-xylosyl backbone with a variety of side chain 
substitutions that vary considerably according to botanic origin and tissue. Arabinoxylan (AX), the 
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C3 or both positions of backbone xylosyl units. Xylan is also present in lower amounts in vegetables and 
fruits as glucuronoxylan[27] (GX), which is decorated with (4-O-methyl)glucuronic acid at the C2 position 
of xylosyl units. Both AX and GX are further acetylated at C2, C3 or both positions. The molecular 
apparatus of xylan utilisation by R. intestinalis has been recently described[5]. Extracellular capture and 
break down of xylan is mediated by a modular xylanase of GH10 (RiXyn10A). This enzyme, which is 
conserved within the species, comprises an N-terminal carbohydrate binding module (CBM) from a 
previously unknown family (henceforth designated as RiCBM86) followed by a CBM22, a GH10 catalytic 
module, a tandem repeat of CBM9 and two C-terminal putative cell-attachment domains. Curiously, 
RiCBM86 was specific to xylan, but it displayed relatively low affinity (KD≈0.5 mM for xylohexaose (X6) as 
opposed to about a 7-fold higher average affinity of the truncated enzyme lacking this CBM for the same 
ligand[5]. Interestingly, RiCBM86 prefers the nutritionally more abundant arabinoxylan as compared to 
glucuronoxylan judged by retardation in affinity electrophoresis gels. 
Association to complex glycans, such as xylan, offers a competitive advantage for bacteria in the densely 
populated milieu of the gut. Firmicutes from Clostridium XIVa group frequently have large modular cell-
attached glycoside hydrolase (GHs) containing multiple carbohydrate binding modules (CBMs) for capture 
and hydrolysis of polysaccharides[5,6,28,29]. To examine the mode of recognition and discrimination of 
RiCBM86 to different xylans, we have determined the structure of this module and performed binding 
analyses to glucurono- and arabinoxylan and oligosaccharides thereof using NMR spectroscopy. RiCBM86 
displays an open and shallow binding site with only direct hydrogen bonds to the C2-OH and C3-OH of a 
single xylosyl moiety, which rationalises the low affinity recognition of xylan. These finding highlight the 
diversity of CBMs associated with xylan catabolism in the human gut and merit further work to bring 
insight into the role of low-affinity glycan recognition in enzymes from this ecological niche. 
Results
Crystal structure
We determined the structure of RiCBM86 in complex with X6. The structure was solved in the hexagonal 
space group P65 (6 molecules in the asymmetric unit) using single-wavelength anomalous diffraction (SAD) 
with the experimental phase information obtained from the Tb anomalous scattering for data collected 
on crystals soaked with Tb-Xo4[30]. The data collection and refinement statistics are in Table 1. The 
structure of RiCBM86 was solved to a maximum resolution of  1.8 Å revealing a β-sandwich fold, 
consisting of two sheets formed by 11 antiparallel β-strands and 2 helical turns (right handed 310-helices) 
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strands β2(K39-G43), β5(Y62-T68), β7(I92-Y97), β8(T108-L112) and β10(D129-I135). β-Sheet 2 is formed 
by β1(V29-T34), β3(D46-A50), β4(G53-F58), β6(N79-A86), β9(E117-I120) and β11(A143-L154). The 
chemical shifts obtained from the NMR assignment are in good agreement with the secondary structure 
in the X-ray structure[31]. A striking feature of the CBM is the open solvent accessible ligand-binding site 
that runs almost orthogonal to the β-strands of sheet 1 (Fig. 1A). A DALI server search against the protein 
data bank (PDB) identified the closest structural relative of RiCBM86 to be CBM29.2 from the fungus 
Piromyces equi[32] (1W9F, Z-score=12.8, primary structure identity 12%), which shows specificity for both 
β-manno- and β-gluco-oligosaccharides[33]. The second closest structural hit is the CBM84 from xanthan 
lyase family 8 of  Paenibacillus nanensis[34] (6F2P, Z-score=11.9). Although the overall structural fold is 
shared between these modules, the low shared sequence identity (<12%) and the divergence of the 
binding sites (especially key residues mediating aromatic stacking onto ligands) justify the assignment of 
RiCBM86 as a representative of a new CBM family.   
Ligand binding site
The crystal structure of RiCBM86 in complex with X6 shows clear density for four xylosyl units. The ligand-
binding site features an open and shallow surface with the ligand bound in a relaxed helical 
conformation[35]. The ligand-binding site is defined by Y110, which stacks onto the terminal reducing end 
moiety of the xylosyl that defines position 1 (Fig. 1B). Xylo-oligosaccharide (XOS) ligands can, however, be 
accommodated in the opposite directionality with equivalent direct hydrogen bonds (non-reducing end 
xylosyl stacking onto Y110), but this seems to be less likely as it places the endocylic oxygen at close 
proximity to the indole ring of W42. Our description will focus on the former orientation for clarity. The 
second aromatic ridge is provided by Y62 that stacks onto the xylosyl unit at position 3. A third potential 
stacking residue is W42 (Fig. 1C). The indole solvent accessible face of this residue, however, is largely 
blocked by a methionine side chain from a neighboring molecule in the crystals. Nonetheless, the terminal 
non-reducing xylosyl at position 4 stacks onto the edge of the indole ring (Fig. 1C). The recognition of the 
helical conformation of the XOS is facilitated by the planes of the aromatic rings of Y62 and Y110 being 
almost orthogonal (≈100˚) to each other (Fig. 1B). The only direct potential hydrogen bonds are observed 
at position 3 between the C2-OH and K95 Nζ, C3-OH and Q64 Nε2, K95 Nζ or D102 Oδ2 (Only two of these 
three potential H-bonds are possible). Additional water mediated potential hydrogen bonds may also 
contribute to the recognition. Dynamic analysis by NMR characterized RiCBM86 as being predominantly 
rigid, with limited flexibility in two loop regions, E71-I73 and G124-A127 as well as the termini (Fig. 2).  
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The changes in 15N-HSQC (heteronuclear single quantum coherence spectroscopy) spectra of RiCBM86 
were monitored and the change in chemical shifts for both the N and H atoms upon titration with 
undecorated xylotetraose (X4), a 1:1 mixture of 33-α-L- and 23-α-L-arabinofuranosyl-xylotetraose (XAXXX) 
and 23-(4-O-methyl-α-D-glucuronyl)-xylotetraose (XUXXX) was followed. The affinity of the RiCBM86 was 
lowest for XUXXX, while the higher affinity for XAXXX and X4 resulted in a chemical shift difference in the 
same order for the two latter ligands (Fig. 3, Table 2). This binding profile and the range of affinity for X4 
are in excellent agreement with the previously reported data[5]. The change in chemical shift occurred 
mainly at the binding site and the flanking area (Fig. 3). The amino acids Y62, Q64, K95, D102 and Y110, 
which are observed to interact with the ligand in the crystal structure, showed a significant chemical shift 
difference after titration with the three ligands, except for Q64 with XUXXX. An interesting observation is 
that G111 undergoes a change in chemical shift in the 1H dimension only for the decorated substrates, 
which is suggestive this region of RiCBM86 may be involved in the accommodation of side chains 
substituted at the C2-OH of the xylosyl at position 1. Neighboring G111, is Y110 which provides aromatic 
stacking interactions for the xylan back bone of substrates. 
The interactions between RiCBM86 and birch glucuronoxylan (BGX) as well as wheat arabinoxylan (WAX) 
were also analyzed by monitoring the 15N-HSQC spectra upon titration (Fig. 4). Due to the strong 
interaction between RiCBM86 and WAX, some of the signals were broadened beyond detection. The 
signals for only the WAX ligand expanded to the backside of the protein. The chemical shift difference was 
lower for BGX, indicating weaker binding affinity to RiCBM86 than WAX. This, in addition to the 
observations made with oligomeric substrates, provides evidence for the preference of RiCBM86 for 
arabinosyl substitutions compared to glucuronosyl substitutions both on XOS and xylan.
Mutational analysis of binding residues 
The crystal structure and the NMR binding analyses suggested that Y62 and Y110 likely provide aromatic 
stacking interactions to two xylosyl units of bound xylan. The edge of the indole ring of W42 makes van 
der Waals contacts with the xylosyl at position 4, which may contribute to restricting the ligand 
confirmation at this site. An alanine scanning mutagenesis approach was used to investigate functional 
significance of the aromatic residues together with the invariant lysine (K95), which recognizes the xylosyl 
at position 3 with a potential bidendate polar interaction (Fig. 1B). The wild type RiCBM86 was 
thermostable with an unfolding temperature Tm= 74.1˚C, which was only modestly affected by the 
mutations based on the identical thermograms under 55˚C (Fig. 5A). This suggests that the overall protein 
structure was retained by the mutants, despite local rearrangements. The binding of the Y62A, K95A and 
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was markedly reduced, especially on WAX (Fig. 5B). The side chain of K95 is crucial for binding as it 
provides the only charged hydrogen bond to the xylosyl ring that is stacked onto Y62. Similarly, each of 
the two aromatic stacking tyrosines Y62 and Y110 is also essential for xylan binding, whereas W42 
contributes to the xylan affinity, albeit to a less extent. This latter residue possibly stabilizes the xylosyl at 
position 4 as observed in the crystal structure. The chemical shift changes of W42 are just above 
significance threshold for XAXXX and X4 and below that for the lower affinity XUXXX, consistent with the 
observed limited contacts of the indole side chain with the XOS ligand. Notably, W42 is conserved in all 
but two homologues of RiCBM86 (see sequence analysis in the next section), which is in agreement with 
the observed impact on the function of the CBM. 
RiCBM86 represent a new family of CBMs from xylanases observed in a taxonomically related Clostridiales  
RiCBM86 confers affinity to xylan and XOS but lacks homologues with an assigned function[5]. A blast 
search against the non-redundant database identified 19 homologs from different butyrate producing 
strains from the Clostridiales order of gut Firmicutes. An analysis of these sequences revealed that several 
structural residues, e.g. glycines and prolines, in addition to residues involved in xylan binding are 
conserved. Members of CBM86 are exclusively located at the N-termini of GH10 xylanases (Fig. 6), which 
together with the narrow distribution among related gut bacteria points to a highly specialized nature of 
these binding modules.
Discussion 
Architecture of the ligand-binding site of RiCBM86 is consistent with low affinity ligand binding.
The ligand-binding site of RiCBM86 features a shallow and open binding surface that accommodates four 
xylosyl units. Only about a 4-fold increase in affinity for X6 was previously observed as compared with 
X4[5], consistent with the presence of only minor additional contacts that stabilise the binding beyond the 
observed X4 ligand similar to other xylan binding modules, e.g. of CBM6[36] and CBM15[37]. The increase 
in affinity could also be due to entropic factors, i.e. more stable helical structure of the longer xylan or 
oligomers thereof as compared to a tetraose. 
The architecture of the binding site of RiCBM86 is different from most type-B xylan specific CBMs[38] e.g. 
from CBM4[39], CBM6[40], CBM15[37] and CBM22[41] (Fig. 7A-E). The deeper and more occluded binding 
site in these latter CBM families is defined by loops connecting the sandwich β-strands and pointing into 
the binding site. By contrast, the equivalent loops in RiCBM86 are pointing downwards and away from the 
ligand, which creates a relatively flat open binding surface topology (Fig. 1). To our knowledge, only a few 
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CBM36[42] (Fig. 7F) and CBM60[43] that are structurally similar to each other. Similarly, to RiCBM86, a 
single xylosyl-binding site dominates ligand recognition in the shallow cleft of these CBMs. A key 
difference, however, between RiCBM86 and CBM36 is that a Ca2+ ion mediates the binding in the latter 
CBM, which appears to yield an affinity about 6-fold higher toward xylohexoase as compared to RiCBM86 
[5,42]. Indeed, the affinity of RiCBM86 to X6 (KD=0.48 mM) is at least 10-fold lower than typical type-B 
xylan-specific CBMs[40,41,44]. While most xylan-binding counterparts from other families typically 
recognize 2−3 xylosyl rings along the binding sites with direct hydrogen bonds[37,44], RiCBM86 has a 
focused recognition of a single xylosyl unit by three direct hydrogen bonds (Fig. 1B). The surface of 
RiCBM86 flanking the active site is mainly negatively charged or apolar, which may explain the 
preferential affinity to arabinoxylan as compared to glucuronic acid substituted xylan (Fig. 1C). Arabinosyl 
decorations are either tolerated or recognized, based on the similar affinities for the undecorated and 
decorated ligand X4 and the markedly higher affinity for WAX as compared to BGX (Fig. 3, 4).
Despite the typical β-sandwich fold observed in CBMs, RiCBM86 does not display high structural similarity 
to any CBM families or other characterized proteins. The closest structural homologues were CBMs with 
affinity to polysaccharides with a different structural symmetry than xylan, such as β-mannan or xanthan. 
Indeed the closest structural homologue is from CBM29, which shares a shallow binding site that prefers 
cello-oligosaccharides (KD =31.4 μM) [32]. The lack of conserved ligand binding residues between 
RiCBM86 and distant functionally described orthologues, is consistent with the functional divergence of 
the new CBM family represented by RiCBM86. To date, 19 non-redundant sequences with high similarity 
to RiCBM86 are retrieved from the NCBI database. Both the aromatic and the polar residues that interact 
with the bound ligand in RiCBM86 are highly conserved in these sequences (Fig. 1B). Additionally 
structurally important amino acid residues such as glycines and a proline are either invariant or highly 
conserved in this new CBM family. 
Rationale for having lower affinity xylan binding in modular xylanase?
Having large extracellular enzymes with a variety of CBMs seems to be common in Clostridiales from the 
human gut. R. intestinalis has a large modular GH26 mannanase with two CBMs[6] and both Eubacterium 
rectale and Butyrivibrio fibrisolvens possess large modular α-amylases with 5 and 2 CBMs, respectively for 
capturing starch[28,45]. RiCBM86 is followed by a CBM22, a GH10 catalytic module and a tandem repeat 
of CBM9 (Fig. 6). Notably the architecture of characterized CBM22 and CBM9 are different from each 









This article is protected by copyright. All rights reserved
accommodate two terminal xylosyl units in xylan [46], whereas CBM22 possess a deep extended binding 
cleft[47,48] for the accommodation of a single xylan chain. Thus, the three different families of CBMs in 
RiXyn10A orchestrate the binding of substrate by being able to capture either the terminal reducing ends 
or internal regions of xylan by the CBM9 (assuming similar binding mode to known members) or 
CBM22/CBM86, respectively. These CBMs also appear to have variable affinities as judged from average 
affinities for X6 of RiCBM86, the full-length enzyme and a truncated variant lacking RiCBM86, which have 
affinities of 479 µM, 128 µM and 65 µM, respectively[5]. Thus, the enzyme construct lacking RiCBM86 
possesses an affinity about 7 fold higher than RiCBM86, which suggests that at least one or more of the 
three remaining CBMs in RiXyn10A possess markedly higher affinities for X6. This variable affinity and 
multiplicity of CBMs may confer a dynamic binding where the substrate is anchored to the enzyme 
surface in between consecutive catalytic cycles to minimize diffusional loss. Notably, similar low affinity 
CBMs in the α-amylase that confers the capture and breakdown of starch by the related gut symbiont E. 
rectale have been reported. Thus, the N-terminal CBM82 and the C-terminal CBM83 of this α-amylase 
displays affinities of ≈1 and 3 mM, respectively to maltoheptaose[45], which is substantially lower than 
the internal CBMs constructs.  Another example of low-affinity (KD≈0.58 mM for the full-length enzyme 
towards β-mannohexoase) CBM from the human gut niche is the mannan specific CBM10 connected to a 
GH5 β-mannanase from Bifidoabcterium animalis subsp. lactis. Interestingly the latter enzyme is one of 
the most efficient β-mannanases reported[13]. The evolution of low affinity CBMs may be an adaptation 
to increase the area of substrate binding with minimal reduction of turnover, i.e. maximizing kcat/koff. 
Additional experiments are required to evaluate the dynamics of substrate binding and translocation to 
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Materials and Methods
Chemicals
All chemical were of analytical grade. Wheat arabinoxylan (WAX), xylohexaose (X6), xylotetraose (X4), 33-
α-L- and-23-α-L-arabinofuranosyl-xylotetraose (XAXXX) in mixture of ≈1:1 were from Megazyme (Wicklow, 
Ireland). 23-(4-O-methyl-α-D-glucuronyl)-xylotetraose (XUXXX) was from Cambridge Glycoscience 
(Cambridge, United Kingdom). Birchwood glucuronoxylan (BGX) was from Carl Roth (Karlsruhe, Germany).
Cloning
The gene fragment encoding the RiCBM86 from Roseburia intestinalis L1-82 was amplified from a plasmid 
encoding the full length xylanase RiXyn10A (EEVO1588.1, ROSINTL182_06494)[5] using a primer pair 
(TTTCAGGGCGCCATGGGGGTAAAAAAAGTTTTTACTGCAGAT, 
GACGGAGCTCGAATTTTAATCCCCCAATTTTGCA). The amplicon, encoding amino acids 28-165 in RiXyn10A, 
was cloned into the EcoRI and NcoI restriction site of a pETM-11 vector (kind gift from Dr. Gunter Stier, 
EMBL, Center for Biochemistry, Heidelberg, Germany)[49] using In-Fusion cloning (Takara). The construct 
was transformed into Escherichia coli DH5α and verified by full sequencing.
Site directed mutagenesis
Specific mutants of RiCBM86 were generated by PCR RiCBM86 as template. The primer pairs were; W42A 
(CAGCTGAAAGTGGCAgcgGGAGACGCGGATTATG, CATAATCCGCGTCTCCcgcTGCCACTTTCAGCTG), Y62A 
(GTCTTTTGCAAAACAGgctAATCAGGTGAAATGGACG, CGTCCATTTCACCTGATTagcCTGTTTTGCAAAAGAC), 
K95A (GTACCGATCAGTCTGgcaGTATACAACGGTGGAGATG, 
CATCTCCACCGTTGTATACtgcCAGACTGATCGGTAC) and Y118A 
(GATTAAGCGGACAGACGGAGgctACGATAAATCCATC, GATGGATTTATCGTagcCTCCGTCTGTCCGCTTAATC). 
The amplicons were incubated with DpnI restriction endonuclease (New England Biolabs) at 37°C for 30 
min to remove the template DNA plasmid. The mutated constructs were then transformed into E. coli 
DH5α and each mutants were sequenced to ensure that only the desired mutations had been 
incorporated into the nucleic acids.
Expression and purification
Recombinant plasmids were transformed into BL21(DE3) (Novagen) for expression of unlabeled and 
13C/15N double labeled protein and B834(DE3) (Novagen) expression selenomethionine labelled protein. 
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labelled protein[11], and double labelled 13C/15N labelled protein used for the NMR studies[31]. Cell 
pellets were resuspended in buffer (20 mM HEPES pH 7.5, 0.5 M NaCl, 10% glycerol) and disrupted at 
1000 bar by a single passage in a high pressure homogenizer (Standsted Fluid Power, Essex, UK). 
Recombinant proteins were purified from the supernatant by affinity chromatography using a 5 mL His-
Trap HP column (GE Healthcare) and a standard protocol. Pure fractions were concentrated and loaded 
onto a Hiload 16/60 Superdex 75 pg size exclusion chromatography column (GE Healthcare) mounted on 
an ÄKTA-AVANT chromatograph (GE Healthcare). For crystallization the His-tag was removed using a TEV-
protease. This was done by buffer exchange into buffer (50 mM Tris-HCL pH 8.0, 0.5 mM EDTA, 1 mM 
DTT) and next adding TEV-protease in a ratio of 1:100 (v/v). After incubation for 24 hours at room 
temperature, the mixture was passes through a His-Trap column, and the flow through containing the 
cleaved protein dialyzed into buffer (20 mM MES pH 6.5, 150 mM NaCl). Protein purity was determined by 
SDS-PAGE and protein concentration were measured spectrophotometrically and calculated from the 
theoretical molar extinction coefficient (ε280nm= 26930 and 23950 M-1 cm-1, for tagged and non-tagged 
proteins, respectively).
Crystallization and structure determination
Crystals were only obtained in the presence of 1 mM X6 by vapour diffusion in hanging or sitting drops, 
and grew for 2 days at 5°C with a 1:1 ratio of the protein (18 mg mL-1  in 10 mM MES pH 6.5 and 150 mM 
NaCl) and reservoir solution (0.2 M Cadmium chloride hemi(pentahydrate) 0.1 M Sodium acetate pH 4.8 
and PEG 400 35% v/v). An initial crystallisation condition (0.1 M Cadmium chloride hemi(pentahydrate), 
0.1 M Sodium acetate pH 4.6 and PEG400 30% v/v at 5 °C) was identified with the Structure Screen 
(Molecular Dimensions Ltd, UK), using a Mosquito® liquid handling robot (TTP Labtech, UK). The crystals 
were flash frozen in liquid nitrogen without cryo-protectant. Diffraction data were collected to a 
maximum resolution of 1.91 and 1.76 Å for derivatized and native crystals respectively, at the DESY 
beamlines, Hamburg, Germany. The dataset was processed with XDS[50]. The structure was solved in the 
hexagonal space group P65 using single-wavelength anomalous diffraction (SAD) with the experimental 
phase information obtained from data collected at 7.575 KeV for crystals soaked for 1 min with 100 mM 
Tb-Xo4[30] (Molecular Dimensions) using the Tb anomalous scatterer for phasing. Experimental phasing, 
initial model building and refinements were performed in the Phenix software suite[51]. Further 
corrections and model building using the program Coot[52]) resulted in a complete model, which was 
used in molecular replacement to  solve the structure of RiCBM86  in a slightly higher resolution dataset. 
Manual structure improvement was done in Coot[52]. Ligand molecules were included after the protein 
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phenix_refine. The overall quality of all models was checked using MolProbity[53].  The data collection 
and refinement statistics are presented in Table 1. The PyMOL Molecular Graphics System, Version 2.0.6 
Schrödinger, LLC was used to explore the models and for rendering.
NMR spectroscopy
NMR spectra of 0.1-0.2 mM RiCBM86 in 50 mM sodium phosphate buffer pH 6.5 and 10% D2O were 
recorded at 25°C on a Bruker Ascend 800 MHz spectrometer Avance III HD (Bruker Biospin) equipped with 
a 5 mm Z-gradient CP-TCI (H/C/N) cryoprobe at the NV-NMR-Centre/Norwegian NMR Platform at NTNU 
(Trondheim, Norway). A single NMR titration was preformed with three oligomeric substrates: X4, XAXXX 
or XUXXX. Titration points for X4 (mM): 0.5, 1.0, 2.5, 5 and 10 M; XAXXX (mM): 0.2, 0.5, 1.0, 2.5, 5.0 and 
10; XUXXX (mM): same as for XAXXX with the addition of the following four points of 12.5, 15.0, 20.0 and 
25.0. In addition, NMR titrations were also carried out with two xylans: BGX and WAX. The titration with 
BGX was performed with nine concentrations within 0.04−1.0 mg mL-1 and a final point at 2.0 mg BGX. For 
WAX eight concentrations within 0.04−0.73 mg mL-1 and a final point of 1.4 mg WAX. 1D and 15N-HSQC 
spectra were recorded for each titration point and processed with Topspin version 3.5 and CARA version 
1.5 using backbone and side-chain assignments of RiCBM86 have been published elsewhere[31]. The 
chemical shift perturbation upon titration was followed in 15N-HSQC. Binding parameters were estimated 
by Gnuplot 5.2 (www.gnuplot.info) using an average of the chemical shift difference (Δ) from the 
titration of three amino acids, KD X4 (A59, N63, N93), KD XAXXX (N63, N93, G111) and KD XUXXX (N63, N93, 
G111).
Relaxation measurements (T1, T2 and 1H-15N NOE) for amide 15N labelled RiCBM86 were recorded. The 
nuclear spin relaxation times T1 and T2 were recorded as pseudo-3D spectra where the two frequency 
dimensions corresponded to the amide 1H and 15N chemical shifts, respectively. The third dimension was 
made up of the following variable relaxation time delays: T1 time points: 0.1, 0.2, 0.5, 1.0, 1.5, 2.0, 2.5, 
3.0, 3.5, 4.0, 4.5 and 5.0 s and T2 time points: 17, 34, 68, 136, 170, 204, 237 and 271 ms. The 
heteronuclear 1H-15N NOE spectra composed of two 2D planes were recorded with and without 
presaturation, respectively. 
Affinity electrophoresis
Binding of RiCBM86 and the mutants to WAX (0.1% w/v) and BGX (1% w/v) was assessed in 10% 
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The thermal stability of the RiCBM86 mutants (1 mg mL-1) was assessed in 10 mM Sodium Phosphate 
buffer, pH 6.5 using differential scanning calorimetry (DSC) between 20°C and 90°C, 1°C min-1 in a Nano 
DSC instrument (TA Instruments, New Castle, DE, USA). Baseline scans, collected with buffer in both 
reference and sample cells, were subtracted from sample scans, and NanoAnalyse (TA Instruments) was 
used to model the reference cell and baseline-corrected thermograms using a two-state model to 
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Tables





Beamline PETRA III P13 PETRA III P13
PDB ID 6SGF
Wavelength (Å) 1.649 1.000
Resolution range (Å) 70.9  - 1.91 (1.98  - 1.91) 46.4  - 1.76 (1.82 - 1.76))
Space group P65 P65
Unit cell 141.87 141.87 60.6 90 90 120 141.87 141.87 60.6 90 90 120
Unique reflections a 53405 (5006) 67325 (4933)
Multiplicity a 9.6 (6.8) 5.8 (1.9)
Completeness (%)a 99.30 (93.65) 96.74 (71.29)
CC½a 0.997 (0.898) 0.998 (0.398)
Mean I/σ(I) a 14.48 (3.21) 15.83 (1.55)
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R-factor 0.1794
R-free 0.2237
Number of atoms 6891
  Macromolecules 5960
  Ligands 248
  Water 683
Protein residues 786
RMS bonds (Å) 0.013
RMS angles (°) 1.68
Ramachandran favored (%) 98.19
Ramachandran outliers (%) 0.00
Clash score 6.97
Average B-factor 26.51
   Macromolecules 25.48
   Ligands 31.97
   Water 33.51
a Values in the parenthesis are for the highest resolution shell.
Table 2 Binding parameters determined by NMR




Binding parameters are estimated from a single titration experiment.
Figure legends
Fig. 1. Crystal structure of RiCBM86. (A) Cartoon model of β-sandwich structure of RiCBM86 (PDB accession: 6SGF). The left panel 
is a top view of sheet 1 formed by five β-strands. The four visible rings of the soaked xylohexaose (X6) are shown in sticks. The 
view is rotated 180° in the right panel to show sheet 2 formed by six β-strands. (B) The left panel is a close-up of the ligand 
binding site with subsites numbered in Arabic numerals starting from the reducing end at position 1. The two aromatic residues 
Y110 and Y62 that stack onto xylosyl rings at positions 1 and 3, respectively. The aromatic side chain of W42 makes limited 
contacts with the xylosyl at position 4, but it is not positioned for aromatic stacking. The only direct hydrogen bonds that 
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for the bound ligand is shown at a contour level of 1σ (blue mesh). The right panel shows the binding site rotated about 90° along 
the axis of the ligand and a sequence logo that reflects the conservation of the binding residues is shown. (C) The electrostatic 
potential of RiCBM86 (at pH=7) is shown to highlight the topology and the chemistry of the ligand binding site. The two aromatic 
stacking residues Y62 and Y110 and W42 are labeled for clarity. The figure was generated with PyMOL.
Fig. 2 Dynamics of RiCBM86 as evaluated by NMR relaxation analysis. 1H-15N NOEs and 15N T1 and T2 relaxation times for RiCBM86 
were recorded at 800 MHz and 25 C.  Apart from two loops (E71-I73 and G124-A127) and the terminals (parts that normally can 
display flexibility), the data shows a well-folded and rigid protein structure. Data are with error bars calculated based on the 
signal-to-noise ratios.
Fig. 3 Interaction of RiCBM86 with xylo-oligosaccharides using NMR chemical shift analysis. The chemical shift differences are 
after titration with xylo-oligosaccharides; (A) glucurono-xylotetraose (XUXXX), (B) α-L-arabinofuranosyl-xylotetraose (XAXXX) and 
(c) xylotetraose (X4). The figure was generated with PyMOL.
Fig. 4 Interaction of RiCBM86 with xylans using NMR chemical shift analysis. The chemical shift differences are after titration with 
xylans; (A) birch glucuronoxylan (BGX) and (B) wheat arabinoxylan (WAX). The figure was generated with PyMOL.
Fig. 5 Analysis of thermal stability and binding to xylan for RiCBM86 and mutants thereof. (A) Reference and baseline subtracted 
differential scanning calorimetry thermograms, which are normalized to protein concentration.  The unfolding temperatures (Tm) 
were determined using a two state model, which is justified due to the partial reversibility of the traces as judged by partial area 
recovery following unfolding. (B) Binding of CBMs to a negative control gel (no polysaccharide), 0.1 (w/v) wheat arabinoxylan 
(WAX) or 1% (w/v) birch glucuronoxylan (BGX) is analyzed using affinity electrophoresis. Lane 1: native marker, lane 2: RiCBM86, 
lane 3: W42A, lane 4: Y62A, lane 5: K95A, lane 6: Y110A. 
Fig. 6 Modular organization of 19 RiCBM86 homologous sequences. The modular organization was predicted using HMMR 
(http://hmmer.org/)[2] and dbCAN (http://bcb.unl.edu/dbCAN2/blast.php)[3]. Purple: novel carbohydrate binding module 
(CBM86), pink: carbohydrate binding module of family 22 (CBM22), yellow: catalytic module of glycoside hydrolase family 10 
(GH10), green: carbohydrate binding module of family 9 (CBM9). The asterisk indicates that this putative CBM9 cannot be 
predicted with these tools, even though it is assigned as CBM9 is the CAZy database. 
Fig. 7 Comparison of the binding site architecture of xylan-specific CBMs. (A) RiCBM86 from Roseburia intestinalis (PDB ID 6SGF), 
(B) CBM4 from Rhodothermus marinus (PDB ID 2Y64), (C) CBM6 from Clostridium stercorarium (PDB ID 2UY4), (D) CBM15 from 
Cellvibrio japonicus (PDB ID 1GNY), (E) CBM22 from Paenibacillus barcinonensis (PDB ID 4XUR), (F) CBM36 from Paenibacillus 
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